{
    "clinical_study": {
        "@rank": "119222", 
        "arm_group": [
            {
                "arm_group_label": "diane-35", 
                "arm_group_type": "Experimental", 
                "description": "Diane-35 pretreatment from the third day of menstrual cycle"
            }, 
            {
                "arm_group_label": "blank control", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to\n      affect more than 5% of the population and is associated with chronically elevated serum\n      androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative\n      impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive\n      disease during pregnancy,and preterm birth,which is partially related with the\n      hyperandrogenic environment.Diane-35 has been proved to be the most effective\n      anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive\n      effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro\n      fertilization/Intracytoplasmic sperm injection."
        }, 
        "brief_title": "the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Polycystic Ovary Syndrome", 
        "condition_browse": {
            "mesh_term": "Polycystic Ovary Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosed polycystic ovary syndrome patients according to Rotterdam criteria\n\n          -  with hyperandrogenism and/or clinical  hyperandrogenic manifestations\n\n          -  no other oral contraceptives treatment for at least 3 months before this experiment\n\n          -  no any other assisted reproductive therapy\n\n          -  accompanied with fallopian tube and/or male factors\n\n          -  normal hepato-/nephro- function\n\n        Exclusion Criteria:\n\n          -  oral contraceptive pills contraindications, eg.Deep Venous Thrombosis\n\n          -  smoking, drunk\n\n          -  exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752270", 
            "org_study_id": "sunyatsen8362"
        }, 
        "intervention": [
            {
                "arm_group_label": "diane-35", 
                "description": "Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.", 
                "intervention_name": "Diane-35 pretreatment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "diane-35", 
                "intervention_name": "Diane-35 pretreatment", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Diane", 
                "Cyproterone", 
                "Cyproterone Acetate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2012", 
        "location": [
            {
                "contact": {
                    "email": "eoshappy@163.com"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510080"
                    }, 
                    "name": "The First Affiliated Hospital of Sun Yatsen University"
                }, 
                "investigator": {
                    "last_name": "Canquan Zhou", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong", 
                        "zip": "510080"
                    }, 
                    "name": "The First Affiliated Hospital of Sun Yatsen University"
                }, 
                "investigator": {
                    "last_name": "Canquan Zhou", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization", 
        "other_outcome": {
            "measure": "clinical pregnancy rate", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2years"
        }, 
        "overall_contact": {
            "email": "eoshappy@163.com", 
            "last_name": "Xiaokun Hu"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "fertilization rate", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752270"
        }, 
        "responsible_party": {
            "investigator_affiliation": "First Affiliated Hospital, Sun Yat-Sen University", 
            "investigator_full_name": "Zhou Canquan", 
            "investigator_title": "vice president", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "implantation rate", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2years"
        }, 
        "source": "First Affiliated Hospital, Sun Yat-Sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "First Affiliated Hospital, Sun Yat-Sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}